Latest news with #KuickResearch
Yahoo
11-07-2025
- Business
- Yahoo
Cancer Antibody Drug Conjugates Treatment Market Size Clinical Trials FDA Approved Report
Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research Delhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales and Clinical Trials Insight 2030 Report Finding & Inclusions: Global Cancer Antibody Drug Conjugates Market: 2020 – 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030 Approved Cancer Antibody Drug Conjugates: 16 Drugs Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company and Indication Download Report: The global cancer antibody-drug conjugate (ADC) market represents one of the most dynamic and rapidly advancing areas in oncologic therapy. ADCs combine the precision targeting of monoclonal antibodies with potent cytotoxic agents, delivering effective treatment directly to cancer cells while sparing healthy tissue. As of July 2025, nineteen ADCs have been approved worldwide, underscoring both clinical acceptance and regulatory momentum. Key approved ADCs include Enhertu (trastuzumab deruxtecan), which generated over US$ 3.75 billion in 2024 sales, led by its strong performance in HER2-positive cancers. Kadcyla (trastuzumab emtansine) also continues to deliver blockbuster revenue, with approximately US$ 2.3 billion in sales in 2024. Other top-performing ADCs include Adcetris (US$ 1.91 billion), Padcev (US$ 1.59 billion), Trodelvy (US$ 1.32 billion), and Polivy (US$ 1.30 billion). The commercial success of these therapies reflects their differentiated clinical value and growing adoption across multiple oncology indications. The market outlook remains strong, with forecasts projecting the ADC segment to surpass US$ 50 billion by 2030, driven by indication expansion, global market penetration, and sustained innovation. The clinical pipeline features over 500 ADC candidates utilizing diverse payloads, bispecific constructs, and next-generation linker technologies. Trials are being conducted globally, with leadership from US and European pharmaceutical companies and rising activity across the Asia-Pacific region—particularly in China, where domestic ADCs such as Aidixi (disitamab vedotin) have gained approval. Approved ADCs have demonstrated significant impact across different tumor targets. Enhertu and Kadcyla underscore the potential of HER2-directed therapy, while agents like Trodelvy (Trop-2), Polivy (CD79b), and Padcev (Nectin-4) exemplify ADC effectiveness in other solid and hematologic malignancies. Patent protection varies across the field, with many agents maintaining extended market exclusivity through novel payload-linker innovations and optimized delivery mechanisms. The ADC clinical pipeline reveals deep innovation. Over 500 molecules are in development, with trials mapped by company, geography, indication, and phase. This breadth enables stakeholders to track development trends across solid and hematologic cancers, with indications expanding into lung, urothelial, ovarian, and beyond. Company-level insights spotlight R&D activity, with several early-stage ADCs progressing into pivotal trials. Commercially approved ADC brands are profiled thoroughly in our report. Enhertu, Kadcyla, Adcetris, Padcev, Polivy, Trodelvy, and newer agents such as Datroway (datopotamab deruxtecan) and Zynlonta (loncastuximab tesirine) are explored in-depth, analyzing mechanisms, development history, regulatory milestones, and indication-specific adoption. This provides a tactical overview of competitive positioning and licensing trends—especially in Asia-Pacific, where local players are launching biosimilar or region-specific ADCs. Our Global Cancer ADC Market Report delivers a comprehensive, data-driven foundation for stakeholders. It includes sales performance and patent analysis for 19 approved ADCs, pricing strategy insights and dosage regimens, pipeline tracking of 500+ clinical ADCs by indication and trial phase, and brand-by-brand commercial intelligence. This resource empowers pharmaceutical executives, biotech investors, and clinical researchers with the insights needed to navigate a sector poised for exponential growth. As ADC therapy evolves, our report is the strategic compass for development prioritization, portfolio building, and market entry planning—at the frontline of oncology Neeraj Chawla Research Head Kuick Research neeraj@ +91-11-47067990 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Market Trends Report
First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Says Kuick Research Delhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals and Future Market Opportunity Outlook 2029 Report: Report Answers Question On Why There Exist Need For Bispecific Antibody Drug Conjugates First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Insight On Bispecific Antibody Drug Conjugates In Clinical Trials : > 60 Drug Conjugates China Dominating Bispecific Antibody Drug Conjugates Clinical Trials: > 35 Drug Conjugates Majority Of Bispecific Antibody Drug Conjugates For Breast Cancer Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Bispecific Antibody Drug Conjugates In Combination Therapy By Indication and Clinical Phase Key Companies Involved In Development Of Bispecific Antibody Drug Conjugates Download Report: The global bispecific antibody drug conjugates (bispecific ADCs) market is emerging as one of the most promising frontiers in next generation targeted therapies. By combining the tumor-targeting precision of bispecific antibodies with the potent cell-killing payloads of ADCs, this modality offers the potential to overcome resistance mechanisms and deliver superior efficacy compared to traditional single-target ADCs or bispecific antibodies alone. As cancer biology becomes increasingly understood, bispecific ADCs are positioned to transform the therapeutic landscape across solid tumors and hematologic malignancies. The first commercial approval of a bispecific ADC is anticipated by 2029, marking a major inflection point for the modality's clinical and commercial potential. Currently, more than 60 bispecific ADCs are under clinical investigation globally, with China leading the research landscape. Over 35 of these bispecific ADCs are being evaluated in Chinese clinical trials, demonstrating the country's rapidly advancing capabilities in next-generation biologics and targeted oncology therapeutics. This dominance is driven by a strong innovation ecosystem, regulatory support for accelerated oncology development, and a growing number of homegrown companies pioneering the space. While the US and Europe also have active pipelines, the sheer scale of China's development efforts provides a competitive edge in candidate volume and trial diversity. Breast cancer remains the primary indication of interest, accounting for the majority of bispecific ADC clinical trials. The focus on breast cancer stems from the availability of well-defined molecular targets such as HER2, HER3, and TROP2, as well as a large patient population with significant unmet clinical needs. Many of these trials are evaluating monotherapy and combination therapy strategies, including checkpoint inhibitors, chemotherapy, and other ADCs, to enhance response rates and prolong survival. Clinical development insights reveal a distribution across early and mid-stage trials, with several assets now progressing from Phase I to Phase II. Our report offers detailed insight into the ongoing clinical trials by company, country, indication, and phase. The July 2025 initiation of Avenzo Therapeutics' first-in-human trial of AVZO-1418/DB-1418 represents a major milestone. Developed in collaboration with DualityBio, this novel EGFR/HER3-targeted bispecific ADC is positioned as a potential best-in-class therapy for advanced solid tumors. The trial underscores growing interest in dual-receptor targeting to overcome tumor heterogeneity and improve therapeutic precision. Another significant update is the July 2025 partnership between Adagene and ConjugateBio. Under this collaboration, Adagene will supply a proprietary antibody for ConjugateBio's bispecific ADC programs, while retaining non-ADC rights. This reflects a growing trend of strategic alliances between antibody innovators and ADC technology companies aimed at accelerating clinical development and enhancing commercial scalability. The competitive landscape is rich and evolving, with companies such as DualityBio, Debiopharm, Adagene, Innovent Biologics, and others at the forefront. Each of these players is leveraging proprietary antibody engineering platforms, novel linker technologies, and high-potency payloads to develop differentiated assets with improved safety and efficacy profiles. The industry is also witnessing increased interest from large pharma companies seeking to co-develop or license bispecific ADC assets to strengthen their oncology portfolios. Our report delivers a comprehensive and strategic analysis of this high-potential market segment. It provides detailed insights into clinical development pipelines, regional dynamics, company-level strategies, technology platforms, and indication-wise trends. With the first approval expected by 2029 and an expanding portfolio of novel assets, the global bispecific antibody-drug conjugate market is poised to play a transformative role in precision oncology. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ +91-11-47067990Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
KIF18A Inhibitor Clinical Trials FDA Approved KIF18A Targeting Therapies Market Report
KIF18A Therapy Commercial Launch Expected By 2030 Says Kuick Research in New Research Study Delhi, June 24, 2025 (GLOBE NEWSWIRE) -- Global KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025 Report Highlights & Findings: First KIF18A Targeting Therapy Commercial Availability Expected By 2030 Highest Phase Of Development: Phase-I/II KIF18A Targeting Therapies In Clinical Trials: > 10 Therapies KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase KIF18A Targeting Therapies Market Development Trends Insight KIF18A Therapies Technology Platforms Insight Download Report: The global oncology landscape is witnessing rapid progress in precision medicine, and one of the most lead nominees in emerging targets is Kinesin Family Member 18A (KIF18A). It is a mitotic motor protein that is essential for chromosome alignment during mitosis, which facilitates proper segregation of chromosomes. Its perturbation leads to genomic instability, which is a distinguishing feature of cancer. Extrapolations of KIF18A have also been seen in various cancers such as ovarian and breast cancer, with an association with prognosis, drug resistance, and the potential to metastasize. As a crucial protein involved in mitosis and overexpression in cancer, KIF18A is now a promising therapeutic target. Targeting KIF18A interferes with mitotic mechanisms in chromosomally unstable (CIN-positive) cancer cells, causing selective death of cancer cells. In contrast to conventional chemotherapies, which indiscriminately impact all proliferating cells, KIF18A inhibitors provide a more selective and less toxic option by taking advantage of cancer cells' vulnerability to proper mitosis. The major approach is small molecule inhibitors that disrupt KIF18A's motor activity, hindering it from modulating microtubule dynamics at the kinetochore. It leads to mitotic arrest and failure of chromosome alignment, ultimately triggering apoptosis in cancer cells. Clinical development is progressing well. Volastra Therapeutics, a forerunner in this arena, is developing two KIF18A-targeting molecules: Sovilnesib (AMG650), acquired from Amgen and underway in Phase I trials for platinum-resistant high-grade serous ovarian cancer, and VLS-1488, an in-house oral inhibitor in Phase I/II. Both molecules displayed favorable safety profiles and early anti-tumor effects, with particular efficacy in high-chromosomal-instability tumors. Volastra's pipeline demonstrates the therapeutic potential of inhibiting KIF18A to treat difficult-to-treat cancers. Accent Therapeutics is also advancing with ATX-295, an oral KIF18A inhibitor in initial clinical testing for solid tumors such as triple-negative breast and high-grade serous ovarian cancers. Their biomarker strategy makes use of genomic instability markers such as whole-genome doubling to better optimize patient selection and optimize therapy outcomes. AI based drug discovery is providing additional impetus to this area. Insilico Medicine has utilized proprietary platforms such as Chemistry42 and PandaOmics to discover ISM9682, a new macrocyclic KIF18A inhibitor with high preclinical efficacy. The AI platforms facilitate rapid optimization of candidates with increased specificity and pharmacological profiles, highlighting the growing use of sophisticated computational approaches in drug discovery. Aside from clinical advancement, the market opportunity for KIF18A inhibitors is also robust. As precision oncology gains more attention, the therapies are well poised to capture the opportunity of targeted therapies, particularly in diseases that are refractory to current treatments. Various companies, including Nvidia-funded Iambic Therapeutics, Aurigene Oncology, Simcere Zaiming Pharmaceutical, and Amgen, are developing promising product candidates in preclinical phases. Overall, the KIF18A-targeted therapy market is changing very quickly, powered by strong scientific justification, initial clinical success, and novel development approaches. As additional preclinical and clinical information becomes available, the market has significant potential for strong growth, powered by partnerships, application of artificial intelligence and machine learning tactics, and the overall dedication to creating targeted and individualized cancer therapeutics. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ in to access your portfolio
Yahoo
05-06-2025
- Business
- Yahoo
FDA Approved Anticancer Peptide Drug Conjugate Market Clinical Trials Insight
Global Peptide Drug Conjugate Market USD 1400 Million Opportunity Says Kuick Research In New Study Delhi, June 05, 2025 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market, Drug Sales, Price, Dosage and Clinical Trials Insight 2030 Report Highlights: Global Peptide Drug Conjugate Market Opportunity: > USD 1400 Million Global Peptide Drug Conjugate Market Trends By Region and Indications Global Peptide Drug Conjugate Market Growth 2018-2024: > 300% Absolute Growth and 27% CAGR Growth Approved Peptide Drug Conjugate Dosage, Sales and Price Insight Approved Peptide Drug Conjugate Sales Global and Regional Insight: 2 Drugs Approved Global Peptide Drug Conjugate Clinical Trials Insight: > 30 Drugs Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Peptide Drug Conjugate Proprietary Technologies and Methodologies Insight By Company Download Report: Peptide drug conjugates constitute a novel category of targeted therapies that make use of disease-targeting peptides to specifically deliver small molecule drugs to the target cells. This blended strategy enables drugs to be targeted more precisely to ailing tissues, minimizing systemic toxicity and maximizing therapeutic benefit. With more than 30 peptide drug conjugates candidates now in different stages of clinical trials, the domain is accelerating at breakneck speed. Most of these candidates are being developed and evaluated for oncology, where the demand for highly targeted therapies is still paramount. Nonetheless, investigations have also been pushed into neurodegenerative disease and inflammatory disorders, which suggests a wider therapeutic scope for this modality. As of May 2025, 2 peptide drug conjugates have been approved by the regulators. Novartis's Lutathera, a radiolabeled peptide for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), exemplifies the potential of targeted delivery in cancer. The second agent that has been approved, Pepaxti (melflufen), by Oncopeptides, is employed to treat multiple myeloma and demonstrates the utility of peptide to enhance the therapeutic index of known cytotoxic agents. All these achievements underscore the potential for peptide drug conjugates and have opened up doors for more firms to enter the pipeline for developing new candidates. Platform technologies are leading the way in driving peptide drug conjugate innovation. For example, PeptiDream's PDPS (Peptide Discovery Platform System) leverages massive libraries of macrocyclic peptides to quickly find high-affinity binders. They are optimized as targeting agents in peptide drug conjugates, enabling more targeted drug delivery. By targeting cytotoxic payloads directly to disease-associated receptors, these technologies reduce off-target effects, improving efficacy and safety for patients. The growing use of such platforms by biotech companies and pharmaceutical companies highlights their significance in the present drug development scenario. Regulatory assistance is also supporting the development of peptide drug conjugates. Sudocetaxel zendusortide (TH1902), a peptide drug conjugate from Theratechnologies, was granted the Fast Track Designation by the FDA. This candidate has been designed against sortilin-expressing solid tumors and is undergoing Phase 1 clinical trials. As the first compound from Theratechnologies' SORT1+ Technology™, it is an example of innovation in peptide targeting and an accelerated regulatory pathway that allows for accelerated development. Designations such as these not only support the therapeutic potential of these compounds but also foster investment and accelerate clinical advancement. The peptide drug conjugate field involves a diverse range of stakeholders, including major pharmaceutical companies like Novartis and Oncopeptides, as well as specialized biotechnology firms such as Bicycle Therapeutics and Theratechnologies. Additionally, contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are increasingly becoming integral to the development process, providing essential services from early-stage discovery through to clinical and commercial manufacturing. In spite of this momentum, market hurdles exist. One major hindrance is the complexity of peptide drug conjugate manufacturing, which sometimes necessitates specialized facilities and intense quality control, potentially pushing up development expense. To overcome it, strategic alliances with seasoned CDMOs can streamline manufacturing and lower operational costs. Regulatory complexity regarding newer payloads or novel peptide-linker chemistries is another hurdle. Anticipation of the regulatory agencies through proactive interaction and utilization of existing designations can smooth over the complexity. Looking to the future, the prospects for peptide-drug conjugates are encouraging. As ever improving technology platforms advance and additional clinical information becomes available, peptide drug conjugates are destined to become a staple of targeted therapy, not just oncology, but perhaps a wide variety of chronic and orphan diseases. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ +91-470679900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight
Chinese Pharmaceutical Companies Dominating Global Research & Development Landscape Of Bispecific ADC Market Says Kuick Research In New Report Delhi, May 29, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals and Future Market Opportunity Outlook 2029 Report: Report Answers Question On Why There Exist Need For Bispecific Antibody Drug Conjugates First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Insight On Bispecific Antibody Drug Conjugates In Clinical Trials : > 60 Drug Conjugates China Dominating Bispecific Antibody Drug Conjugates Clinical Trials: > 35 Drug Conjugates Majority Of Bispecific Antibody Drug Conjugates For Breast Cancer Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Bispecific Antibody Drug Conjugates In Combination Therapy By Indication and Clinical Phase Key Companies Involved In Development Of Bispecific Antibody Drug Conjugates Download Report: Bispecific antibody drug conjugates (BsADCs) are an innovative class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies with the cytotoxic payloads characteristic of traditional antibody drug conjugates (ADCs). Unlike conventional ADCs, which typically target a single antigen, BsADCs engage two different antigens simultaneously, enhancing specificity and efficacy against cancer cells. This unique mechanism enables BsADCs to not only deliver cytotoxic agents directly to the tumor site but also improve selectivity for cancer cells, potentially reducing off-target effects. The development of BsADCs is supported by various advanced technology platforms. For instance, Alphamab Oncology has developed a proprietary ADC platform that allows for the precise construction of bispecific constructs. Similarly, Bi-Cygni Therapeutics employs its BiVictriX platform to enhance the efficacy and safety profiles of its bispecific antibodies. Debiopharm's Multilink™ platform is another example that enables the creation of multifunctional biotherapeutics. These technology platforms play a crucial role in optimizing the design and development of BsADCs, streamlining the path from research to clinical application. One of the most advanced bispecific antibody drug conjugates currently in development is BL B01D1, created by Sichuan Baili Pharmaceutical and its subsidiary, SystImmune. This candidate is undergoing clinical trials in China, showcasing the country's rapid advancements in this therapeutic area. With a focus on addressing unmet medical needs, BL B01D1 exemplifies the potential of BsADCs to provide effective treatment options for patients facing challenging cancers. The ongoing trials will provide valuable data on its safety and efficacy, contributing to the broader understanding of bispecific therapies. China has emerged as a dominant force in the development of BsADCs, with a significant number of clinical trials underway. This landscape is marked by intense competition, as various companies strive to launch their candidates and establish themselves as leaders in this burgeoning field. Notable players include ABL Bio, Bristol Myers Squibb, Amgen, Debiopharm, Doma Bio, ProEn Therapeutics, AstraZeneca, and Innovent Biologics. Each of these companies is racing to bring their innovative therapies to market, aiming to be the first in their class. As the market for bispecific antibody drug conjugates becomes increasingly competitive, the ongoing research and development will likely yield numerous advancements that could redefine cancer treatment paradigms. The potential of BsADCs to deliver targeted therapy more effectively than conventional ADCs makes them an exciting prospect in oncology. With continued investment and innovation, these therapeutics could significantly improve patient outcomes, offering new hope in the fight against cancer. The landscape is rapidly evolving, and as clinical data emerges, the true impact of bispecific antibody drug conjugates will begin to take shape, highlighting their role in the future of cancer treatment. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
